|
|
|
| Research progress of thermal ablation therapy for metastatic lung cancer |
| WANG Houze DU Ming |
| Department of Thoracic Surgery,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China |
|
|
|
|
Abstract Lung is one of the most common metastatic sites of malignant tumors.In recent years,percutaneous tumor ablation has attracted more and more attention due to its minimally invasive approach,and it has become a new treatment for metastatic lung cancer patients who have lost the opportunity of surgery.Radiofrequency ablation,microwave ablation and cryoablation are three widely used thermal ablation methods in the lung.Among them,radiofrequency ablation and microwave ablation induce molecular collision and friction in tumor tissues through the application of alternating high-frequency current or electromagnetic field oscillation,generating heat to achieve coagulation necrosis of tumor cells.Several studies have reported the safety and efficacy of these two ablation methods for metastatic lung cancer,but there is still a lack of randomized controlled trials to provide more evidence-based medical evidence for the use of this technology.Cryoablation of target lesions at low temperature leads to protein denaturation,cell membrane rupture,and microvascular thrombosis,thereby inducing cell death and tissue injury.Cryoablation is currently a hot topic in the field of ablation therapy,and it has performed well in the latest prospective studies.However,the existing survival data are limited,especially the long-term follow-up data are still lacking.Each of the three ablation methods for metastatic lung cancer has its advantages and disadvantages.The specific selection of ablation methods needs to be evaluated by multiple disciplines according to the patient's condition and the actual situation of each center,and an individualized treatment plan should be formulated.In view of the increasing clinical demand,this paper reviews the current research progress of thermal ablation therapy for metastatic lung cancer,with a view to assisting clinical decision-making.
|
|
|
|
|
|
|
|
|
